Between the N-Assay and the new virus diagnostic t

Between the N-Assay and the new virus diagnostic tool, no one Company would be able to afford to buy the Company outright. Of course, this all depends on how widely the existence of these technologies becomes known and how much time elapses before the majority of shareholders lose patience and want to cash out on any decent offer ($5? $10? $20?....$100?).

The Company does not have the infrastructure or the means at present to grow a diagnostic company organically. It would require significant investment in money, time and expertise. Time is the most precious due to the pace of technologies and innovation.

Assuming the cat is out of the bag (lots of competing interest), I think the Company is best suited to take in royalties from licensing its tech. I have no idea what a typical setup would be, but I imagine a lump sum up front, a relatively large % up to the first 'x' million in revenues followed by a perpetual lower %.

I tried, but couldn't get to a satisfactory number. Suffice it to say I gladly give my vote for a buyout if offered anything over $10...possibly less given how long its been. lol.